Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy

Pharmacological Research

Volumn 66, Issue 5, 2012, Pages 419-427

  Martinez Becerra, P ^a   Monte, I ^a   Romero, M R ^a,e   Serrano, M A ^a,e   Vaquero, J ^a   MacIas, R I R ^a,e   Del Rio, A ^b   Grane Boladeras N ^c,e   Jimenez, F ^a,d,e   San Martin, F Gonzalez ^a,d,e   Pastor Anglada, M ^c,e   Marin, J J G ^a,e  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Gastroenterology Unit   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Chemoresistance; Colorectal adenocarcinoma; MDR phenotype; Taqman Low Density Arrays; Tumour

Indexed keywords

CISPLATIN; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR ALPHA1; FARNESOID X RECEPTOR ALPHA2; GUGGULSTERONE; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; COLORECTAL CARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; PHARMACOGENETICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN ISOFORMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84866729039     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.07.005     Document Type: Article

References (40)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: Globocan 2008 International Journal of Cancer 127 2010 2893 2917
2. L. Bujanda, C. Sarasqueta, E. Hijona, L. Hijona, A. Cosme, and I. Gil Colorectal cancer prognosis twenty years later World Journal of Gastroenterology 16 2010 862 867
3. D.J. Gallagher, and N. Kemeny Metastatic colorectal cancer: from improved survival to potential cure Oncology 78 2010 237 248
4. J.J. Marin, M.R. Romero, P. Martinez-Becerra, E. Herraez, and O. Briz Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours Current Molecular Medicine 9 2009 1108 1129
5. J.K. Kemper Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications Biochimica et Biophysica Acta 1812 2011 842 850
6. M.J. Monte, M.A. Serrano, E. Herraez, J. Vaquero, E. Gonzalez-Sanchez, and M.R. Romero Chemoresistance can be induced by bile acid-independent activation of FXR in liver and intestinal cancer cells Hepatology 54 2011 713 714
7. J.J. Eloranta, and G.A. Kullak-Ublick The role of FXR in disorders of bile acid homeostasis Physiology (Bethesda) 23 2008 286 295
8. O. Briz, R.I. Macias, M. Vallejo, A. Silva, M.A. Serrano, and J.J. Marin Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors Molecular Pharmacology 63 2003 742 750
9. J. Cui, L. Huang, A. Zhao, J.L. Lew, J. Yu, and S. Sahoo Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump Journal of Biological Chemistry 278 2003 10214 10220
10. R.I. Macias, C. Hierro, S. Cuesta de Juan, F. Jimenez, F. Gonzalez-San Martin, and J.J. Marin Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases British Journal of Nutrition 106 2011 1814 1825
11. V.G. Tusher, R. Tibshirani, and G. Chu Significance analysis of microarrays applied to the ionizing radiation response Proceedings of the National Academy of Sciences of the United States of America 98 2001 5116 5121
12. A.I. Saeed, N.K. Bhagabati, J.C. Braisted, W. Liang, V. Sharov, and E.A. Howe TM4 microarray software suite Methods in Enzymology 411 2006 134 193
13. Y. Huang, and W. Sadee Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells Cancer Letters 239 2006 168 182
14. T. Abe, M. Unno, T. Onogawa, T. Tokui, T.N. Kondo, and R. Nakagomi LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers Gastroenterology 120 2001 1689 1699
15. J.J. Marin, M.R. Romero, and O. Briz Molecular bases of liver cancer refractoriness to pharmacological treatment Current Medicinal Chemistry 17 2010 709 740
16. A. Yonezawa, S. Masuda, S. Yokoo, T. Katsura, and K. Inui Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family) Journal of Pharmacology and Experimental Therapeutics 319 2006 879 886
17. L.M. Chan, S. Lowes, and B.H. Hirst The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability European Journal of Pharmaceutical Sciences 21 2004 25 51
18. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, and M.C. Willingham Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proceedings of the National Academy of Sciences of the United States of America 84 1987 7735 7738
19. T. Efferth, V.B. Konkimalla, Y.F. Wang, A. Sauerbrey, S. Meinhardt, and F. Zintl Prediction of broad spectrum resistance of tumors towards anticancer drugs Clinical Cancer Research 14 2008 2405 2412
20. M.R. Ballestero, M.J. Monte, O. Briz, F. Jimenez, F. Gonzalez-San Martin, and J.J. Marin Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps Biochemical Pharmacology 72 2006 729 738
21. E. Hinoshita, T. Uchiumi, K. Taguchi, N. Kinukawa, M. Tsuneyoshi, and Y. Maehara Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas Clinical Cancer Research 6 2000 2401 2407
22. V. Pavillard, C. Agostini, S. Richard, V. Charasson, D. Montaudon, and J. Robert Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines Cancer Chemotherapy and Pharmacology 49 2002 329 335
23. K. Tanimoto, M. Kaneyasu, T. Shimokuni, K. Hiyama, and M. Nishiyama Human carboxylesterase 1a2 expressed from carboxylesterase 1a1 and 1a2 genes is a potent predictor of CPT-11 cytotoxicity in vitro Pharmacogenetics and Genomics 17 2007 1 10
24. A.C. Lazaris, N.G. Kavantzas, H.S. Zorzos, N.V. Tsavaris, and P.S. Davaris Markers of drug resistance in relapsing colon cancer Journal of Cancer Research and Clinical Oncology 128 2002 114 118
25. P.G. Johnston, H.J. Lenz, C.G. Leichman, K.D. Danenberg, C.J. Allegra, and P.V. Danenberg Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Research 55 1995 1407 1412
26. M.C. Etienne, M. Chazal, P. Laurent-Puig, N. Magne, C. Rosty, and J.L. Formento Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses Journal of Clinical Oncology 20 2002 2832 2843
27. S. Marsh, J.A. McKay, J. Cassidy, and H.L. McLeod Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer International Journal of Oncology 19 2001 383 386
28. E. Chu, D.M. Koeller, P.G. Johnston, S. Zinn, and C.J. Allegra Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma Molecular Pharmacology 43 1993 527 533
29. T. Kuwai, T. Nakamura, T. Sasaki, Y. Kitadai, J.S. Kim, and R.R. Langley Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy Clinical and Experimental Metastasis 25 2008 477 489
30. R. Leite de Oliveira, A. Hamm, and M. Mazzone Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies Molecular Aspects of Medicine 32 2011 71 87
31. D.A. Delmastro, J. Li, A. Vaisman, M. Solle, and S.G. Chaney DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines Cancer Chemotherapy and Pharmacology 39 1997 245 253
32. D. Fink, S. Aebi, and S.B. Howell The role of DNA mismatch repair in drug resistance Clinical Cancer Research 4 1998 1 6
33. M.G. Ormerod, C. O'Neill, D. Robertson, L.R. Kelland, and K.R. Harrap Cis-diamminedichloroplatinum(ii)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines Cancer Chemotherapy and Pharmacology 37 1996 463 471
34. Y. Xu, F. Fang, G. Ludewig, G. Jones, and D. Jones A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells DNA and Cell Biology 23 2004 419 429
35. S. Huerta, J.H. Heinzerling, Y.M. Anguiano-Hernandez, S. Huerta-Yepez, J. Lin, and D. Chen Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: Roles of FAS, APAF-1, NFKappaB, IAPS, Smac/Diablo, and AIF Journal of Surgical Research 142 2007 184 194
36. D. Arango, J.M. Mariadason, A.J. Wilson, W. Yang, G.A. Corner, and C. Nicholas C-myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis British Journal of Cancer 89 2003 1757 1765
37. A. Petitjean, E. Mathe, S. Kato, C. Ishioka, S.V. Tavtigian, and P. Hainaut Impact of mutant p53 functional properties on tp53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC tp53 database Human Mutation 28 2007 622 629
38. D.A. Dart, S.M. Picksley, P.A. Cooper, J.A. Double, and M.C. Bibby The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment International Journal of Oncology 24 2004 115 125
39. D. Arango, A.J. Wilson, Q. Shi, G.A. Corner, M.J. Aranes, and C. Nicholas Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells British Journal of Cancer 91 2004 1931 1946
40. T.P. Burris, C. Montrose, K.A. Houck, H.E. Osborne, W.P. Bocchinfuso, and B.C. Yaden The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand Molecular Pharmacology 67 2005 948 954